12:00 AM
Sep 10, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Nexvax2: Phase Ib started

ImmusanT began a double-blind, placebo-controlled, U.S. Phase Ib trial to evaluate multiple ascending-doses of intradermal Nexvax2 in about 36 patients. Becton Dickinson and Co. (NYSE:BDX, Franklin Lakes, N.J.) is supplying to ImmusanT intradermal...

Read the full 153 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >